A"verdict"on the economic value of the patent system by the US economist Fritz Machlup published in 1958 still has an important impact on assessing the effects of the patent system on economic development by...A"verdict"on the economic value of the patent system by the US economist Fritz Machlup published in 1958 still has an important impact on assessing the effects of the patent system on economic development by intellec-tual property scholars worldwide.This contribution analyses Machlup's study as is and in the light of subsequent US and global legal and economic developments.Machlup's assessment was examined based on empirical data generated by the US Bayh-Dole type legislation as regards the translation of basic research into innovative products and pro-cesses.Moreover,it analyses the impact of the new world economic order instituted in the framework of the World Trade Organization(WTO)mandatorily requiring effective patent protection in all WTO Member States on the eco-nomic development of developing and emerging economies.The case of China,which adopted its first Patent Law in 1984,is addressed in the context of Machlup's verdict and in light of the subsequent economic,scientific and techno-logical development of that country.Concluding thoughts consider today's value of Machlup's"verdict".展开更多
When the human society steps into a new epoch, we, in cooperation with the World Intellectual Property Organization (WIPO), hold the Sino-African Intellectual Property Forum, on which we may exchange experiences in de...When the human society steps into a new epoch, we, in cooperation with the World Intellectual Property Organization (WIPO), hold the Sino-African Intellectual Property Forum, on which we may exchange experiences in developing intellectual property systems and discuss issues of common concern. The themes listed in the agenda not only mirror the emerging issues of the development of the international intellectual property system, but also carry significant weight to展开更多
On January 1,1994, China formally became a member state of the Patent Cooperation Treaty (PCT), and the Patent Office of the People’s Republic of China an international patent search and preliminary examination unit ...On January 1,1994, China formally became a member state of the Patent Cooperation Treaty (PCT), and the Patent Office of the People’s Republic of China an international patent search and preliminary examination unit of the PCT. The Chinese language also became one of the official languages of the PCT. This means that Chinese can be used to展开更多
This study aimed to evaluate the feasibility,safety,and efficacy of a noveltranscatheter suture closure system(HaloStitch^(®))for patent foramen ovale(PFO)closure in a swine model.Methods:Thirteen swine underwent...This study aimed to evaluate the feasibility,safety,and efficacy of a noveltranscatheter suture closure system(HaloStitch^(®))for patent foramen ovale(PFO)closure in a swine model.Methods:Thirteen swine underwentexperimental PF0 model creation.All animals received implantationof the transcatheter suture closure system to evaluate procedural success.Comprehensive follow-up over sixmonths included serial ultrasound imaging,histopathological analysis,and gross anatomical exaninationof cardiac specimens.Results:Successful HaloStitch^(®)device implantation was adhieved in 11 of 13 swine.Gross anatomical examination confirrned secure positioning of all sutures in the atrial septum,with noredundancy or thrombus formation.Postoperative ultrasound demonstrated stable suture and staplepositions throughout follow-up,with no evidence of suture breakage,displacement,or thrombus.Stapleswere clearly visualized under ultrasound imaging,Both the atrial septal defect orifice diameter and residualseptal shunt flow velocity decreased significantly during the observation period.Histopathological analysisrevealed partially organized thrombi at the implant head and fibrous connective tissue encapsulation withlocalized inflammatory cell infiltration surrounding the polymer material.Conclsions:The transcathetersuture closure system(HaloStitch^(®))demonstrated feasibility,safety,and biocompatib ility for PFO closure ina swine model,supporting its potential for clinical translation.展开更多
AIM To investigate if patent foramen ovale(PFO) closure device reduces the risk of recurrent stroke in patients with cryptogenic stroke.METHODS We searched five databases-Pub Med,EMBASE,Cochrane,CINAHL and Web-of-Scie...AIM To investigate if patent foramen ovale(PFO) closure device reduces the risk of recurrent stroke in patients with cryptogenic stroke.METHODS We searched five databases-Pub Med,EMBASE,Cochrane,CINAHL and Web-of-Science and clinicaltrials.gov from January 2000 to September 2017 for randomized trials comparing PFO closure to medical therapy in cryptogenic stroke.Heterogeneity was determined using Cochrane's Q statistics.Random effects model was used.RESULTS Five randomized controlled trials with 3440 patients were included in the analysis.Mean follow-up was 50 ± 20 mo.PFO closure was associated with a 41% reduction in incidence of recurrent strokes when compared to medical therapy alone in patients with cryptogenic stroke [risk ratio(RR): 0.59,95%CI: 0.40-0.87,P = 0.008].Atrial fibrillation was higher with device closure when compared to medical therapy alone(RR: 4.97,95%CI: 2.22-11.11,P < 0.001).There was no difference between the two groups with respect to all-cause mortality,major bleeding or adverse events.CONCLUSION PFO device closure in appropriately selected patients with moderate to severe right-to-left shunt and/or atrial septal aneurysm shows benefit with respect to recurrent strokes,particularly in younger patients.Further studies are essential to evaluate the impact of higher incidence of atrial fibrillation seen with the PFO closure device on long-term mortality and stroke rates.展开更多
Objective:To evaluate the effectiveness and safety of seven oral Chinese patent medicines(CPMs)as adjuvant therapy for cancer-related anemia(CRA)by network meta-analysis(NMA).Methods:A literature search to obtain rand...Objective:To evaluate the effectiveness and safety of seven oral Chinese patent medicines(CPMs)as adjuvant therapy for cancer-related anemia(CRA)by network meta-analysis(NMA).Methods:A literature search to obtain randomized controlled trials(RCTs)of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022.The RevMan5.3 and R 4.1.1 software were used for NMA.Results:We ultimately included 29 RCTs with 2140 patients.Traditional meta-analysis showed that Fufang E'jiao syrup(FFEJS),Shengxuebao mixture(SXBM),Shengxuening tablets(SXNT),Jianpi Shengxue granules(JPSXG),and Yixuesheng capsule(YXSC)combined with basic Western treatment(BWT)could improve the hemoglobin(HGB)level.JPSXG combined with BWT could improve the red blood cell(RBC).FFEJS combined with BWT improved the Karnofsky performance status(KPS).NMA showed that FFEJS,JPSXG,SXBM,and SXNT plus BWT improved HGB better than Shengxue tablets(SXT)plus BWT,with top three ranking results being JPSXG plus BWT>SXNT plus BWT>FFEJS plus BWT.FFEJS plus BWT,JPSXG plus BWT,SXBM plus BWT,SXNT plus BWT,and SXT plus BWT improved RBC better than BWT,with top three ranking results being SXNT plus BWT>JPSXG plus BWT>FFEJS plus BWT.In terms of the KPS score,compared with SXT plus BWT,FFEJS,JPSXG,SXBM,SXNT,and Yizhong Shengxue capsule(YZSXC)plus BWT had higher KPS,with top three ranking results being SXBM plus BWT>JPSXG plus BWT>FFEJS plus BWT.Conclusions:Our NMA demonstrated that seven oral CPMs used as adjuvant treatment of CRA had a definite clinical effect.JPSXG not only increases the levels of HGB and RBC to enhance the clinical effect but also improves patients'quality of life.More accurate conclusions need to be verified by more high-quality RCTs.展开更多
Traditional Chinese patent medicines (TCPMs) are widely used for treatment of chronic hepatitis B (CHB) in China. To estimate the overall effectiveness of TCPMs for CHB, we performed a systematic review of clinical re...Traditional Chinese patent medicines (TCPMs) are widely used for treatment of chronic hepatitis B (CHB) in China. To estimate the overall effectiveness of TCPMs for CHB, we performed a systematic review of clinical reports designed as randomized controlled trials (RCTs). One hundred and thirty-eight available RCTs and quasi-RCTs on 62 TCPMs, involving 16,393 patients, were included. The methodological quality of these trials was generally "poor". Few trials (6.52%) reported the methods of randomization correctly. Another common problem was the lack of allocation concealment, proper blinding, and the reporting of lost cases and dropouts. Forty-two trials (30.43%) on 27 TCPMs reported some anti-viral effect of TCPMs. Others reported beneficial aspects, including improvements of liver function (79.71% of the studies), liver fibrosis (29.99%), and CHB symptoms (92.75%). Forty-one articles (29.71%) reported mild adverse events with TCPMs but these occurred infrequently. In summary, the outcome of the report on currently registered TCPMs may be biased due to poor methodology. The data from these trials, therefore, is too weak to use in forming a recommendation for treatment of CHB. Nevertheless, five drugs (Dan Shen agents, Da Huang Zhe Chong pill/capsule, Shuang Hu Qing Gan granule, Fu Zheng Hua Yu granule and Cao Xian Yi Gan capsule) appear to be more effective than the other TCPMs.展开更多
OBJECTIVE:To synthesize the evidence from randomized controlled trials(RCTs)to assess the efficacy and safety of Chinese patent medicine(CPM)on atherosclerosis(AS)or with a high risk of atherosclerosis.METHODS:All RCT...OBJECTIVE:To synthesize the evidence from randomized controlled trials(RCTs)to assess the efficacy and safety of Chinese patent medicine(CPM)on atherosclerosis(AS)or with a high risk of atherosclerosis.METHODS:All RCTs in three databases(Pub Med,EMBASE,and Cochrane Library)were included from the inception of the database to September 20,2019.The methodological evaluation of the included trials was carried out using the Cochrane Collaboration Risk of Bias Tool.Meta-analysis was conducted using Rev Man 5.3 software.The Grading of Recommendations Assessment,Development and Evaluation(GRADE)methodology was used to evaluate the quality of evidence.RESULTS:Eighteen RCTs were included,involving a total of 3885 patients with AS or with a high risk of AS.Most trials had favorable methodology.Meta-analysis suggested significant differences in clinical endpoint(n=1938,RR 0.53;95%CI 0.40 to 0.69,P<0.00001;I^(2)=0%);the change in carotid artery IMT(n=1723,MD-0.09,95%CI-0.14 to-0.04,P<0.001;I^(2)=40%);change in FMD(n=239,MD 0.87,95%CI 0.52 to 1.21,P<0.00001;I^(2)=0%);change in high sensitive C-reactive protein(hsCRP)(n=1527,MD-1.89,95%CI-3.36 to-0.42,P=0.01;I^(2)=94%)and incidence of total adverse events(RR 0.76,95%CI 0.62 to 0.93,P=0.009;I^(2)=40%)in favor of the experimental group.However,meta-analysis showed no significant differences in the change in lowdensity lipoprotein-C(LDL-C)(n=2419,MD-0.19,95%CI-0.50 to 0.12,P=0.22,I^(2)=94%)between the experimental and control groups.Conclusion:CPM could have certain clinical efficacy in the treatment of AS.However,more double-blinded placebo-controlled RCTs are required in further evaluations to provide stronger evidence.展开更多
Background:Persistent patent ductus arteriosus(pPDA)is a common condition in preterm infants.This metaanalysis aimed to assess the safety and efficacy of transcatheter closure(TC)when compared to surgical ligation(SL)...Background:Persistent patent ductus arteriosus(pPDA)is a common condition in preterm infants.This metaanalysis aimed to assess the safety and efficacy of transcatheter closure(TC)when compared to surgical ligation(SL)in preterm infants with pPDA.Methods:A literature search of Ovid Cochrane Library,Medline,Embase,Epub,Scopus,PMC Preprints,and ClinicalTrials.Gov was conducted from inception to May 06,2022.Eligible studies reported infants diagnosed with pPDA born at≤2000 g birth weight or at≤37 weeks’who underwent TC or SL as treatment.This review was registered in PROSPERO(CRD42022325944).Results:From 97 studies screened,8 studies met the eligibility criteria,with a total of 756 preterm infants undergoing either TC(n=366)or SL(n=390).Compared to TC,SL had higher mortality rates(OR=0.32,95%CI:0.16,0.66,I^(2)=0%).No difference was seen in post-procedural complication rate(OR=0.90,95%CI:0.18,4.44,I^(2)=79%),mean duration of post-procedural mechanical ventilation(MD=−2.21 days,95%CI:−4.88,0.47,I^(2)=60%),hospital stay length(MD=−8.30 days,95%CI:−17.03,0.44,I^(2)=0%)or neonatal intensive care unit stay length(MD=−3.50 days,95%CI:−10.27,3.27,I^(2)=0%).Conclusion:Our meta-analysis demonstrated TC as a viable alternative option in managing preterm infants with pPDA in the context of SL.Despite the promising trends demonstrated in this meta-analysis,further studies with larger sample size and controlled baseline characteristics are needed to evaluate the safety and efficacy of TC and SL for preterm infants with pPDA.展开更多
Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Databa...Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Database"in https://db.yaozh.com/,collect Chinese patent medicines for the treatment of digestive system tumors,establish an Excel table,and use the ancient and modern medical case cloud platform(V2.2.1)to perform frequency statistics,association rules,and drugs on the data Clustering and complex network analysis.Results:A total of 36 Chinese patent medicines for the treatment of digestive system tumors were screened.The medicinal properties were mainly warm and cold,the taste was bitter and sweet,and the meridians were mainly liver and spleen meridians.High frequency Chinese medicine include Astragalus,Scutellaria-barbata,Ginseng,Curcuma,Triangle,Atractylodes,Hedyotis diffusa,etc.Correlation analysis obtained 17 drug combinations,High-frequency drug pairs include Scutellaria-barbata-Astragalus,Ginseng-Astragalus,Curcuma-Astragalus,Scutellaria-barbata-Curcuma,etc.Cluster analysis found 3 types of drugs.The core drug network is composed of 27 drugs,and the core compatibility network consists of 3 groups of drugs.Conclusion:The Chinese patent compound medicine for the treatment of digestive system tumors has the characteristics of combining cold and warming,replenishing and reducing treatment,and treating the liver and spleen at the same time.The medicine is mainly used to replenish qi and invigorate the spleen,promote blood circulation and remove blood stasis,and clear away heat and detoxification.Replenish qi,nourish yin,invigorate blood,and detoxify are mainly compatible with each other,reflecting the pathogenesis characteristics of"deficiency,stasis,and toxin"in digestive system tumors.Data mining can provide references for the prescription and compatibility of Chinese patent medicines.展开更多
Recently the importance of intellectual property has been increased. There has been various ways of research on analy- sis of companies, forecast of technology and so on through patents and many investments of money a...Recently the importance of intellectual property has been increased. There has been various ways of research on analy- sis of companies, forecast of technology and so on through patents and many investments of money and time. Unlike traditional method of patent analysis such as company analysis, forecasting technologies, this research is to suggest the ways to forecast registration and rejection of patents which help minimize the efforts to register patents. To do so, in- formation such as inventors, applicants, application date, and IPC codes were extracted to be used as input variables for analyzing Bayesian network. Especially, among various forms of Bayesian network, we used Tree Augmented NBN (TAN) to forecast registration and rejection of patent. This is because, TAN was assumed to have dependence between variables. As a result of this Bayesian network, it was shown that there are nearly more than 80% of accuracy to fore- cast registration and rejection of patents. Therefore, we expect the minimization of time and cost of registration by forecasting registration and rejection of R&D patent through this research.展开更多
Summary This paper analyses the turbine bypass system design and operation mode for domestically made 300 MW unit with technology imported, and put forward some suggestions about whether bypass system is needed. 1.0 I...Summary This paper analyses the turbine bypass system design and operation mode for domestically made 300 MW unit with technology imported, and put forward some suggestions about whether bypass system is needed. 1.0 Introduction The domestically made WH Co, patent 300 MW unit is produced according to the technology of American Westinghouse (WH) Corporation. The original展开更多
Rapid and accurate identification of high-quality patents can accelerate the transformation process of scientific and technological achievements, optimize the management of intellectual property rights and enhance the...Rapid and accurate identification of high-quality patents can accelerate the transformation process of scientific and technological achievements, optimize the management of intellectual property rights and enhance the vitality of innovation. Aiming at the shortcomings of the traditional high-value patent assessment method, which is relatively simple and seldom considers the influence of patentees, this paper proposes a high-quality patent method HMFM (High-Value Patent Multi-Feature Fusion Method) that fuses multi-dimensional features. A weighted node importance assessment method in complex network called GLE (Glob-Local-struEntropy) based on improved structural entropy is designed to calculate the influence of the patentee to form the patentee’s features, and the patent text features are extracted by BERT-DPCNN deep learning model, which is supplemented to the basic patent indicator system. Finally a machine learning algorithm is used to assess the value of patents. Experiment results show that our method can identify high-value patents more effectively and accurately.展开更多
Stable angina pectoris is a common condition that affects a wide group of patients with coronary artery diseases.A number of Chinese patent drugs based on classic herbal formulations are available for angina managemen...Stable angina pectoris is a common condition that affects a wide group of patients with coronary artery diseases.A number of Chinese patent drugs based on classic herbal formulations are available for angina management.A network meta-analysis is proposed to assess the relative efficacy and safety of commonly used drugs for stable angina and generate a clinically meaningful ranking for each important outcome.We composed a list of 24 widely-used oral blood-quickening Chinese patent drugs from literature review and expert consultation.Three English and five Chinese electronic databases will be searched up to July 2021 for randomised clinical trials comparing between drugs on the list or with nitrates or placebo for stable angina.Unpublished data or grey literature will be sought through trial registries and correspondence to the report authors.Two reviewers independently screen literature,extract data and assess clinical and methodological features of included studies.The WinBUGS software will be used to perform network meta-analysis and the Stata 13.0 software to generate graphic demonstrations of the results.Primary outcomes are the incidence of cardiovascular events and changes in angina frequency,duration and intensity.We will use the surface under the cumulative ranking curve and the mean value for the numeric presentation of efficacy and safety ranking probabilities of multiple treatments.Heterogeneity and inconsistency will be assessed using appropriate statistical tests,and subgroup analysis and network meta-regression will be resorted when necessary.The quality of evidence for each outcome will be graded with the web-based GRADEpro GDT.展开更多
Objective To explore the extent to which the drug-patent linkage system should be implemented in China. Methods The present situation of drug-patent linkage system internationally was analyzed. Then the practices of d...Objective To explore the extent to which the drug-patent linkage system should be implemented in China. Methods The present situation of drug-patent linkage system internationally was analyzed. Then the practices of drug-patent linkage system were discussed through such methods as literature reviews and quantitative scoring methods in combination of selecting the representative countries. Finally the extent to which the drugpatent linkage system should be implemented in China was explored through comparative analysis. Results and Conclusion Compared with the United States, China should establish a drug-patent linkage system that will weaken the protection of original patented drugs and promote the timely marketing of high-quality generic drugs and appropriately prevent the patent abuse.展开更多
Objective Randomized controlled trials(RCTs)of Chinese patent medicines and classic tra-ditional Chinese medicine prescriptions were systematically reviewed from both Chinese and English journals published in 2023.A p...Objective Randomized controlled trials(RCTs)of Chinese patent medicines and classic tra-ditional Chinese medicine prescriptions were systematically reviewed from both Chinese and English journals published in 2023.A preliminary summary and evaluation were conducted on the generation and translation of clinical evidence for these treatments.This analysis aims to inform future research on clinical efficacy evaluation and guide the rational application of evidence.Methods RCTs of Chinese patent medicines and classic traditional Chinese prescriptions published in 2023 were comprehensively retrieved from the Artificial Intelligence Clinical Evi-dence Database for Chinese Patent Medicine(AICED-CPM),with supplementary searches conducted in China National Knowledge Infrastructure(CNKI),Wanfang Data,Chinese Sci-ence and Technology Journal Database(VIP),Chinese Biomedical Literature Database(SinoMed),Cochrane Library,PubMed,Embase,and Web of Science.The study characteris-tics and methodological quality of these RCTs were systematically analyzed and evaluated.Results A total of 1443 RCTs of Chinese patent medicines were included,comprising 1399 Chinese articles and 44 English articles.Additionally,334 RCTs of classic traditional Chinese medicine prescriptions were found,with 331 published in Chinese and 3 in English.196567 participants were included,covering 585 types of Chinese patent medicines(487 oral,61 in-jectable,and 37 topical)and 179 classic traditional Chinese medicine prescriptions.The in-volved studies encompassed 22 types of diseases,with research primarily focusing on dis-eases of the circulatory system,the respiratory system,and the genitourinary system.The sample sizes ranged from 18 to 3777 participants,and most studies were conducted at a sin-gle center.Methodologically,the implementation of allocation concealment and blinding re-mained insufficiently emphasized.Conclusion Overall,compared with 2022,both the number of RCT publications and their methodological quality have improved in 2023,with heightened attention to research on diseases of the genitourinary system.However,quality control and standardized management in the design and implementation processes still require enhancement to produce more high-quality clinical evidence and accelerate the translation and application of this evidence.展开更多
Objective To provide some suggestions and countermeasures for improving the patent evaluation system in pharmaceutical enterprises.Methods Literature research method was used to collect the relevant documents of pharm...Objective To provide some suggestions and countermeasures for improving the patent evaluation system in pharmaceutical enterprises.Methods Literature research method was used to collect the relevant documents of pharmaceutical enterprises and patent evaluation system,and then the problems of traditional patent evaluation methods for pharmaceutical patents were studied.Results and Conclusion The evaluation of pharmaceutical patents plays an important role for pharmaceutical enterprises.However,it is urgent to improve the pharmaceutical patent evaluation system because there are many difficulties in evaluating pharmaceutical patents,such as large fluctuation of patent value,strong subjective interference,the incomplete pharmaceutical information,unapplicable traditional evaluation method,and the insufficient role of evaluation agencies.Therefore,some suggestions are put forward:(1)The application of the real option method;(2)Developing evaluation institutions and training evaluation personnel;(3)Improving the laws and policies related to the evaluation of pharmaceutical patents;(4)Building a pharmaceutical patent evaluation database.展开更多
BACKGROUND The Food and Drug Administration has approved percutaneous atrial septal defect(ASD)and patent foramen ovale(PFO)closure devices for hemodynamically significant interatrial shunts,paradoxical emboli includi...BACKGROUND The Food and Drug Administration has approved percutaneous atrial septal defect(ASD)and patent foramen ovale(PFO)closure devices for hemodynamically significant interatrial shunts,paradoxical emboli including stroke,and decompression sickness.We aimed to study the trends in utilization and reimbursements of transcatheter ASD/PFO closure devices.AIM To analyze trends in utilization and Medicare reimbursements for transcatheter ASD/PFO closure procedures from 2013 to 2022.METHODS A query of administrative data on United States Medicare beneficiaries undergoing transcatheter ASD/PFO was conducted from 2013 to 2022 using the Centers for Medicare and Medicaid Services Part B National Summary Data File.Inflation adjustments were made using the 2023 Consumer Price Index.Trend analysis was quantified using growth rate and simple linear regression calculations.All analyses were performed using Microsoft Excel 16.77.1(2023).RESULTS The annual number of transcatheter ASD/PFO closure procedures increased by 81%since 2013,with an average yearly growth rate of 44%cases per year(P<0.001).Annual Medicare reimbursements for transcatheter ASD/PFO therapies mirrored the annual procedure trends.The per-case reimbursements decreased by 18%,i.e.,$1128.80 in 2013 and$770.21 in 2022(P<0.001).There was a significant drop in the number of procedures in the year 2020,which correlates to the onset of the coronavirus disease 2019 pandemic,followed by a sharp uptick in the number of cases in 2021 and 2022.CONCLUSION Medicare utilization of transcatheter ASD/PFO closure therapies has grown significantly in procedural volume from 2013 to 2022.However,this has been accompanied by a decrease in per-case reimbursements.展开更多
While the significant role of technological innovation in promoting renewable energy has been extensively explored in the literature,limited attention has been paid to the impact of energy patents,particularly clean e...While the significant role of technological innovation in promoting renewable energy has been extensively explored in the literature,limited attention has been paid to the impact of energy patents,particularly clean energy patents and fossil fuel patents.This study pioneers an investigation into the effects of energy patents and energy prices on renewable energy consumption.The study utilizes data from 2000Q1 to 2023Q4 and,due to the nonlinear nature of the series,applies wavelet quantile-based methods.Specifically,it introduces the wavelet quantile cointegration approach to evaluate cointegration across different quantiles and time horizons,along with the wavelet quantile-on-quantile regression method.The results confirm cointegration across different periods and quantiles,highlighting the significant relationships between energy patents,economic factors,and renewable energy consumption.Furthermore,we found that fossil energy patents negatively affect renewable energy consumption,while clean energy patents have a similar but weaker effect,especially in the short term.In addition,higher energy prices promote renewable energy adoption while economic growth positively influences renewable energy consumption,particularly in the short term.The study formulates specific policies based on these findings.展开更多
文摘A"verdict"on the economic value of the patent system by the US economist Fritz Machlup published in 1958 still has an important impact on assessing the effects of the patent system on economic development by intellec-tual property scholars worldwide.This contribution analyses Machlup's study as is and in the light of subsequent US and global legal and economic developments.Machlup's assessment was examined based on empirical data generated by the US Bayh-Dole type legislation as regards the translation of basic research into innovative products and pro-cesses.Moreover,it analyses the impact of the new world economic order instituted in the framework of the World Trade Organization(WTO)mandatorily requiring effective patent protection in all WTO Member States on the eco-nomic development of developing and emerging economies.The case of China,which adopted its first Patent Law in 1984,is addressed in the context of Machlup's verdict and in light of the subsequent economic,scientific and techno-logical development of that country.Concluding thoughts consider today's value of Machlup's"verdict".
文摘When the human society steps into a new epoch, we, in cooperation with the World Intellectual Property Organization (WIPO), hold the Sino-African Intellectual Property Forum, on which we may exchange experiences in developing intellectual property systems and discuss issues of common concern. The themes listed in the agenda not only mirror the emerging issues of the development of the international intellectual property system, but also carry significant weight to
文摘On January 1,1994, China formally became a member state of the Patent Cooperation Treaty (PCT), and the Patent Office of the People’s Republic of China an international patent search and preliminary examination unit of the PCT. The Chinese language also became one of the official languages of the PCT. This means that Chinese can be used to
基金supported by grants from National High-Level Hospital Clinical Research Funding(2023-GSP-RC-04).
文摘This study aimed to evaluate the feasibility,safety,and efficacy of a noveltranscatheter suture closure system(HaloStitch^(®))for patent foramen ovale(PFO)closure in a swine model.Methods:Thirteen swine underwentexperimental PF0 model creation.All animals received implantationof the transcatheter suture closure system to evaluate procedural success.Comprehensive follow-up over sixmonths included serial ultrasound imaging,histopathological analysis,and gross anatomical exaninationof cardiac specimens.Results:Successful HaloStitch^(®)device implantation was adhieved in 11 of 13 swine.Gross anatomical examination confirrned secure positioning of all sutures in the atrial septum,with noredundancy or thrombus formation.Postoperative ultrasound demonstrated stable suture and staplepositions throughout follow-up,with no evidence of suture breakage,displacement,or thrombus.Stapleswere clearly visualized under ultrasound imaging,Both the atrial septal defect orifice diameter and residualseptal shunt flow velocity decreased significantly during the observation period.Histopathological analysisrevealed partially organized thrombi at the implant head and fibrous connective tissue encapsulation withlocalized inflammatory cell infiltration surrounding the polymer material.Conclsions:The transcathetersuture closure system(HaloStitch^(®))demonstrated feasibility,safety,and biocompatib ility for PFO closure ina swine model,supporting its potential for clinical translation.
文摘AIM To investigate if patent foramen ovale(PFO) closure device reduces the risk of recurrent stroke in patients with cryptogenic stroke.METHODS We searched five databases-Pub Med,EMBASE,Cochrane,CINAHL and Web-of-Science and clinicaltrials.gov from January 2000 to September 2017 for randomized trials comparing PFO closure to medical therapy in cryptogenic stroke.Heterogeneity was determined using Cochrane's Q statistics.Random effects model was used.RESULTS Five randomized controlled trials with 3440 patients were included in the analysis.Mean follow-up was 50 ± 20 mo.PFO closure was associated with a 41% reduction in incidence of recurrent strokes when compared to medical therapy alone in patients with cryptogenic stroke [risk ratio(RR): 0.59,95%CI: 0.40-0.87,P = 0.008].Atrial fibrillation was higher with device closure when compared to medical therapy alone(RR: 4.97,95%CI: 2.22-11.11,P < 0.001).There was no difference between the two groups with respect to all-cause mortality,major bleeding or adverse events.CONCLUSION PFO device closure in appropriately selected patients with moderate to severe right-to-left shunt and/or atrial septal aneurysm shows benefit with respect to recurrent strokes,particularly in younger patients.Further studies are essential to evaluate the impact of higher incidence of atrial fibrillation seen with the PFO closure device on long-term mortality and stroke rates.
基金This work was supported by the National Natural Science Foundation of China(82074240)the Capital Health Research and Development of Special(2020-2-4193).
文摘Objective:To evaluate the effectiveness and safety of seven oral Chinese patent medicines(CPMs)as adjuvant therapy for cancer-related anemia(CRA)by network meta-analysis(NMA).Methods:A literature search to obtain randomized controlled trials(RCTs)of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022.The RevMan5.3 and R 4.1.1 software were used for NMA.Results:We ultimately included 29 RCTs with 2140 patients.Traditional meta-analysis showed that Fufang E'jiao syrup(FFEJS),Shengxuebao mixture(SXBM),Shengxuening tablets(SXNT),Jianpi Shengxue granules(JPSXG),and Yixuesheng capsule(YXSC)combined with basic Western treatment(BWT)could improve the hemoglobin(HGB)level.JPSXG combined with BWT could improve the red blood cell(RBC).FFEJS combined with BWT improved the Karnofsky performance status(KPS).NMA showed that FFEJS,JPSXG,SXBM,and SXNT plus BWT improved HGB better than Shengxue tablets(SXT)plus BWT,with top three ranking results being JPSXG plus BWT>SXNT plus BWT>FFEJS plus BWT.FFEJS plus BWT,JPSXG plus BWT,SXBM plus BWT,SXNT plus BWT,and SXT plus BWT improved RBC better than BWT,with top three ranking results being SXNT plus BWT>JPSXG plus BWT>FFEJS plus BWT.In terms of the KPS score,compared with SXT plus BWT,FFEJS,JPSXG,SXBM,SXNT,and Yizhong Shengxue capsule(YZSXC)plus BWT had higher KPS,with top three ranking results being SXBM plus BWT>JPSXG plus BWT>FFEJS plus BWT.Conclusions:Our NMA demonstrated that seven oral CPMs used as adjuvant treatment of CRA had a definite clinical effect.JPSXG not only increases the levels of HGB and RBC to enhance the clinical effect but also improves patients'quality of life.More accurate conclusions need to be verified by more high-quality RCTs.
基金supported by Hunan Natural Science Foundation (09JJ3065)
文摘Traditional Chinese patent medicines (TCPMs) are widely used for treatment of chronic hepatitis B (CHB) in China. To estimate the overall effectiveness of TCPMs for CHB, we performed a systematic review of clinical reports designed as randomized controlled trials (RCTs). One hundred and thirty-eight available RCTs and quasi-RCTs on 62 TCPMs, involving 16,393 patients, were included. The methodological quality of these trials was generally "poor". Few trials (6.52%) reported the methods of randomization correctly. Another common problem was the lack of allocation concealment, proper blinding, and the reporting of lost cases and dropouts. Forty-two trials (30.43%) on 27 TCPMs reported some anti-viral effect of TCPMs. Others reported beneficial aspects, including improvements of liver function (79.71% of the studies), liver fibrosis (29.99%), and CHB symptoms (92.75%). Forty-one articles (29.71%) reported mild adverse events with TCPMs but these occurred infrequently. In summary, the outcome of the report on currently registered TCPMs may be biased due to poor methodology. The data from these trials, therefore, is too weak to use in forming a recommendation for treatment of CHB. Nevertheless, five drugs (Dan Shen agents, Da Huang Zhe Chong pill/capsule, Shuang Hu Qing Gan granule, Fu Zheng Hua Yu granule and Cao Xian Yi Gan capsule) appear to be more effective than the other TCPMs.
基金National Natural Science Foundation of China:Regulation of nanomedicine on the immune microenvironment in the macrophage-rich area of arterial plaques based on IL-17 immunity(No.82274279,to Q.L.)。
文摘OBJECTIVE:To synthesize the evidence from randomized controlled trials(RCTs)to assess the efficacy and safety of Chinese patent medicine(CPM)on atherosclerosis(AS)or with a high risk of atherosclerosis.METHODS:All RCTs in three databases(Pub Med,EMBASE,and Cochrane Library)were included from the inception of the database to September 20,2019.The methodological evaluation of the included trials was carried out using the Cochrane Collaboration Risk of Bias Tool.Meta-analysis was conducted using Rev Man 5.3 software.The Grading of Recommendations Assessment,Development and Evaluation(GRADE)methodology was used to evaluate the quality of evidence.RESULTS:Eighteen RCTs were included,involving a total of 3885 patients with AS or with a high risk of AS.Most trials had favorable methodology.Meta-analysis suggested significant differences in clinical endpoint(n=1938,RR 0.53;95%CI 0.40 to 0.69,P<0.00001;I^(2)=0%);the change in carotid artery IMT(n=1723,MD-0.09,95%CI-0.14 to-0.04,P<0.001;I^(2)=40%);change in FMD(n=239,MD 0.87,95%CI 0.52 to 1.21,P<0.00001;I^(2)=0%);change in high sensitive C-reactive protein(hsCRP)(n=1527,MD-1.89,95%CI-3.36 to-0.42,P=0.01;I^(2)=94%)and incidence of total adverse events(RR 0.76,95%CI 0.62 to 0.93,P=0.009;I^(2)=40%)in favor of the experimental group.However,meta-analysis showed no significant differences in the change in lowdensity lipoprotein-C(LDL-C)(n=2419,MD-0.19,95%CI-0.50 to 0.12,P=0.22,I^(2)=94%)between the experimental and control groups.Conclusion:CPM could have certain clinical efficacy in the treatment of AS.However,more double-blinded placebo-controlled RCTs are required in further evaluations to provide stronger evidence.
文摘Background:Persistent patent ductus arteriosus(pPDA)is a common condition in preterm infants.This metaanalysis aimed to assess the safety and efficacy of transcatheter closure(TC)when compared to surgical ligation(SL)in preterm infants with pPDA.Methods:A literature search of Ovid Cochrane Library,Medline,Embase,Epub,Scopus,PMC Preprints,and ClinicalTrials.Gov was conducted from inception to May 06,2022.Eligible studies reported infants diagnosed with pPDA born at≤2000 g birth weight or at≤37 weeks’who underwent TC or SL as treatment.This review was registered in PROSPERO(CRD42022325944).Results:From 97 studies screened,8 studies met the eligibility criteria,with a total of 756 preterm infants undergoing either TC(n=366)or SL(n=390).Compared to TC,SL had higher mortality rates(OR=0.32,95%CI:0.16,0.66,I^(2)=0%).No difference was seen in post-procedural complication rate(OR=0.90,95%CI:0.18,4.44,I^(2)=79%),mean duration of post-procedural mechanical ventilation(MD=−2.21 days,95%CI:−4.88,0.47,I^(2)=60%),hospital stay length(MD=−8.30 days,95%CI:−17.03,0.44,I^(2)=0%)or neonatal intensive care unit stay length(MD=−3.50 days,95%CI:−10.27,3.27,I^(2)=0%).Conclusion:Our meta-analysis demonstrated TC as a viable alternative option in managing preterm infants with pPDA in the context of SL.Despite the promising trends demonstrated in this meta-analysis,further studies with larger sample size and controlled baseline characteristics are needed to evaluate the safety and efficacy of TC and SL for preterm infants with pPDA.
基金Beijing Municipal Administration of Traditional Chinese Medicine Project(No.2019-ZX-005)。
文摘Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Database"in https://db.yaozh.com/,collect Chinese patent medicines for the treatment of digestive system tumors,establish an Excel table,and use the ancient and modern medical case cloud platform(V2.2.1)to perform frequency statistics,association rules,and drugs on the data Clustering and complex network analysis.Results:A total of 36 Chinese patent medicines for the treatment of digestive system tumors were screened.The medicinal properties were mainly warm and cold,the taste was bitter and sweet,and the meridians were mainly liver and spleen meridians.High frequency Chinese medicine include Astragalus,Scutellaria-barbata,Ginseng,Curcuma,Triangle,Atractylodes,Hedyotis diffusa,etc.Correlation analysis obtained 17 drug combinations,High-frequency drug pairs include Scutellaria-barbata-Astragalus,Ginseng-Astragalus,Curcuma-Astragalus,Scutellaria-barbata-Curcuma,etc.Cluster analysis found 3 types of drugs.The core drug network is composed of 27 drugs,and the core compatibility network consists of 3 groups of drugs.Conclusion:The Chinese patent compound medicine for the treatment of digestive system tumors has the characteristics of combining cold and warming,replenishing and reducing treatment,and treating the liver and spleen at the same time.The medicine is mainly used to replenish qi and invigorate the spleen,promote blood circulation and remove blood stasis,and clear away heat and detoxification.Replenish qi,nourish yin,invigorate blood,and detoxify are mainly compatible with each other,reflecting the pathogenesis characteristics of"deficiency,stasis,and toxin"in digestive system tumors.Data mining can provide references for the prescription and compatibility of Chinese patent medicines.
文摘Recently the importance of intellectual property has been increased. There has been various ways of research on analy- sis of companies, forecast of technology and so on through patents and many investments of money and time. Unlike traditional method of patent analysis such as company analysis, forecasting technologies, this research is to suggest the ways to forecast registration and rejection of patents which help minimize the efforts to register patents. To do so, in- formation such as inventors, applicants, application date, and IPC codes were extracted to be used as input variables for analyzing Bayesian network. Especially, among various forms of Bayesian network, we used Tree Augmented NBN (TAN) to forecast registration and rejection of patent. This is because, TAN was assumed to have dependence between variables. As a result of this Bayesian network, it was shown that there are nearly more than 80% of accuracy to fore- cast registration and rejection of patents. Therefore, we expect the minimization of time and cost of registration by forecasting registration and rejection of R&D patent through this research.
文摘Summary This paper analyses the turbine bypass system design and operation mode for domestically made 300 MW unit with technology imported, and put forward some suggestions about whether bypass system is needed. 1.0 Introduction The domestically made WH Co, patent 300 MW unit is produced according to the technology of American Westinghouse (WH) Corporation. The original
文摘Rapid and accurate identification of high-quality patents can accelerate the transformation process of scientific and technological achievements, optimize the management of intellectual property rights and enhance the vitality of innovation. Aiming at the shortcomings of the traditional high-value patent assessment method, which is relatively simple and seldom considers the influence of patentees, this paper proposes a high-quality patent method HMFM (High-Value Patent Multi-Feature Fusion Method) that fuses multi-dimensional features. A weighted node importance assessment method in complex network called GLE (Glob-Local-struEntropy) based on improved structural entropy is designed to calculate the influence of the patentee to form the patentee’s features, and the patent text features are extracted by BERT-DPCNN deep learning model, which is supplemented to the basic patent indicator system. Finally a machine learning algorithm is used to assess the value of patents. Experiment results show that our method can identify high-value patents more effectively and accurately.
基金supported by the National Natural Science Foundation of China(No.81603495)the Administration of Traditional Chinese Medicine of Tianjin Health Commission(No.2019072).
文摘Stable angina pectoris is a common condition that affects a wide group of patients with coronary artery diseases.A number of Chinese patent drugs based on classic herbal formulations are available for angina management.A network meta-analysis is proposed to assess the relative efficacy and safety of commonly used drugs for stable angina and generate a clinically meaningful ranking for each important outcome.We composed a list of 24 widely-used oral blood-quickening Chinese patent drugs from literature review and expert consultation.Three English and five Chinese electronic databases will be searched up to July 2021 for randomised clinical trials comparing between drugs on the list or with nitrates or placebo for stable angina.Unpublished data or grey literature will be sought through trial registries and correspondence to the report authors.Two reviewers independently screen literature,extract data and assess clinical and methodological features of included studies.The WinBUGS software will be used to perform network meta-analysis and the Stata 13.0 software to generate graphic demonstrations of the results.Primary outcomes are the incidence of cardiovascular events and changes in angina frequency,duration and intensity.We will use the surface under the cumulative ranking curve and the mean value for the numeric presentation of efficacy and safety ranking probabilities of multiple treatments.Heterogeneity and inconsistency will be assessed using appropriate statistical tests,and subgroup analysis and network meta-regression will be resorted when necessary.The quality of evidence for each outcome will be graded with the web-based GRADEpro GDT.
文摘Objective To explore the extent to which the drug-patent linkage system should be implemented in China. Methods The present situation of drug-patent linkage system internationally was analyzed. Then the practices of drug-patent linkage system were discussed through such methods as literature reviews and quantitative scoring methods in combination of selecting the representative countries. Finally the extent to which the drugpatent linkage system should be implemented in China was explored through comparative analysis. Results and Conclusion Compared with the United States, China should establish a drug-patent linkage system that will weaken the protection of original patented drugs and promote the timely marketing of high-quality generic drugs and appropriately prevent the patent abuse.
基金National Multidisciplinary Innovation Team of Traditional Chinese Medicine (ZYYCXTD-D-202204)Science and Technology Project of Haihe Laboratory of Modern Chinese Medicine (22HHZYSS00013)。
文摘Objective Randomized controlled trials(RCTs)of Chinese patent medicines and classic tra-ditional Chinese medicine prescriptions were systematically reviewed from both Chinese and English journals published in 2023.A preliminary summary and evaluation were conducted on the generation and translation of clinical evidence for these treatments.This analysis aims to inform future research on clinical efficacy evaluation and guide the rational application of evidence.Methods RCTs of Chinese patent medicines and classic traditional Chinese prescriptions published in 2023 were comprehensively retrieved from the Artificial Intelligence Clinical Evi-dence Database for Chinese Patent Medicine(AICED-CPM),with supplementary searches conducted in China National Knowledge Infrastructure(CNKI),Wanfang Data,Chinese Sci-ence and Technology Journal Database(VIP),Chinese Biomedical Literature Database(SinoMed),Cochrane Library,PubMed,Embase,and Web of Science.The study characteris-tics and methodological quality of these RCTs were systematically analyzed and evaluated.Results A total of 1443 RCTs of Chinese patent medicines were included,comprising 1399 Chinese articles and 44 English articles.Additionally,334 RCTs of classic traditional Chinese medicine prescriptions were found,with 331 published in Chinese and 3 in English.196567 participants were included,covering 585 types of Chinese patent medicines(487 oral,61 in-jectable,and 37 topical)and 179 classic traditional Chinese medicine prescriptions.The in-volved studies encompassed 22 types of diseases,with research primarily focusing on dis-eases of the circulatory system,the respiratory system,and the genitourinary system.The sample sizes ranged from 18 to 3777 participants,and most studies were conducted at a sin-gle center.Methodologically,the implementation of allocation concealment and blinding re-mained insufficiently emphasized.Conclusion Overall,compared with 2022,both the number of RCT publications and their methodological quality have improved in 2023,with heightened attention to research on diseases of the genitourinary system.However,quality control and standardized management in the design and implementation processes still require enhancement to produce more high-quality clinical evidence and accelerate the translation and application of this evidence.
文摘Objective To provide some suggestions and countermeasures for improving the patent evaluation system in pharmaceutical enterprises.Methods Literature research method was used to collect the relevant documents of pharmaceutical enterprises and patent evaluation system,and then the problems of traditional patent evaluation methods for pharmaceutical patents were studied.Results and Conclusion The evaluation of pharmaceutical patents plays an important role for pharmaceutical enterprises.However,it is urgent to improve the pharmaceutical patent evaluation system because there are many difficulties in evaluating pharmaceutical patents,such as large fluctuation of patent value,strong subjective interference,the incomplete pharmaceutical information,unapplicable traditional evaluation method,and the insufficient role of evaluation agencies.Therefore,some suggestions are put forward:(1)The application of the real option method;(2)Developing evaluation institutions and training evaluation personnel;(3)Improving the laws and policies related to the evaluation of pharmaceutical patents;(4)Building a pharmaceutical patent evaluation database.
文摘BACKGROUND The Food and Drug Administration has approved percutaneous atrial septal defect(ASD)and patent foramen ovale(PFO)closure devices for hemodynamically significant interatrial shunts,paradoxical emboli including stroke,and decompression sickness.We aimed to study the trends in utilization and reimbursements of transcatheter ASD/PFO closure devices.AIM To analyze trends in utilization and Medicare reimbursements for transcatheter ASD/PFO closure procedures from 2013 to 2022.METHODS A query of administrative data on United States Medicare beneficiaries undergoing transcatheter ASD/PFO was conducted from 2013 to 2022 using the Centers for Medicare and Medicaid Services Part B National Summary Data File.Inflation adjustments were made using the 2023 Consumer Price Index.Trend analysis was quantified using growth rate and simple linear regression calculations.All analyses were performed using Microsoft Excel 16.77.1(2023).RESULTS The annual number of transcatheter ASD/PFO closure procedures increased by 81%since 2013,with an average yearly growth rate of 44%cases per year(P<0.001).Annual Medicare reimbursements for transcatheter ASD/PFO therapies mirrored the annual procedure trends.The per-case reimbursements decreased by 18%,i.e.,$1128.80 in 2013 and$770.21 in 2022(P<0.001).There was a significant drop in the number of procedures in the year 2020,which correlates to the onset of the coronavirus disease 2019 pandemic,followed by a sharp uptick in the number of cases in 2021 and 2022.CONCLUSION Medicare utilization of transcatheter ASD/PFO closure therapies has grown significantly in procedural volume from 2013 to 2022.However,this has been accompanied by a decrease in per-case reimbursements.
文摘While the significant role of technological innovation in promoting renewable energy has been extensively explored in the literature,limited attention has been paid to the impact of energy patents,particularly clean energy patents and fossil fuel patents.This study pioneers an investigation into the effects of energy patents and energy prices on renewable energy consumption.The study utilizes data from 2000Q1 to 2023Q4 and,due to the nonlinear nature of the series,applies wavelet quantile-based methods.Specifically,it introduces the wavelet quantile cointegration approach to evaluate cointegration across different quantiles and time horizons,along with the wavelet quantile-on-quantile regression method.The results confirm cointegration across different periods and quantiles,highlighting the significant relationships between energy patents,economic factors,and renewable energy consumption.Furthermore,we found that fossil energy patents negatively affect renewable energy consumption,while clean energy patents have a similar but weaker effect,especially in the short term.In addition,higher energy prices promote renewable energy adoption while economic growth positively influences renewable energy consumption,particularly in the short term.The study formulates specific policies based on these findings.
